News

Stereotaxis today announced a global collaboration with Abbott to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems.

Continuous monitoring of common arrhythmia leads to early intervention and improved rhythm control

New data from three late-breaking clinical trials supports pulsed field ablation as treatment option for atrial fibrillation 

Novel treatment offers non-pharmacological approach for treating common blood circulation disorder

Findings from two new studies highlight the success of left bundle branch area pacing, or his-bundle pacing, as an alternative to biventricular pacing for patients requiring cardiac resynchronization therapy.

Results from a pivotal clinical trial found a leadless pacemaker can deliver cardiac resynchronization therapy (CRT) among patients who were not able to be treated with conventional CRT and epicardial leads.

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker

- Study Led by John Mignone, M.D., Ph.D., Presented at the Heart Rhythm Society’s Annual Meeting - Key Findings Demonstrate Increased Survival for Patients Receiving Combined Device and 4-Class Medical Therapy

BIOTRONIK’s first ICM with SmartECG, an intelligent system with advanced algorithms, receives FDA approval

-Additional real-world outcomes further demonstrate safety, efficacy and procedural reproducibility of the FARAPULSE™ Pulsed Field Ablation System* -Results from global trial of the POLARx™ Cryoablation System* meet safety and effectiveness...